Zithromax, Azithromycin News

Azithromycin is a generic variant of Pfizer 's Zithromax and is ADD-Vantage system compatible.

Tuesday, 30 June 2009, 2:52 pm Press Release: PHARMAC Following is a media release from PHARMAC.

LAKE FOREST,A Ill. Hospira, the world leader in generic injectable pharmaceuticals, announced the Food and Drug Administration has approved its 500 mg vial of azithromycin for injection in the ADD-Vantage System.

Lack of Macrolide Resistance in Chlamydia trachomatis after Mass Azithromycin Distributions for Trachoma Kevin Cyrus Hong, Julius Schachter, Jeanne Moncada, Zhaoxia Zhou, Jenafir House, and Thomas M. Lietman Author affiliation: University of California, San Francisco, California, USA Abstract We investigated antimicrobial drug resistance in ocular ...

Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.

A comparison of fluoroquinolones versus other antibiotics for treating enteric fever: meta-analysis British Medical Journal.

Fears have been raised over strains of drug resistant gonorrhoea that have emerged in England and Wales.

OBJECTIVES: To review evidence supporting use of fluoroquinolones as first line agents over other antibiotics for treating typhoid and paratyphoid fever .

Cempra Pharmaceuticals Inc. raised $46 million in a Series C financing to continue clinical trials with the two antibiotic programs it licensed three years ago from Optimer Pharmaceuticals Inc.

May 4, 2009 - Inspire Pharmaceuticals, Inc. announced today the presentation of data related to post-marketing open-label clinical and nonclinical work with AzaSite 1% in poster presentations at the 2009 Association for Research in Vision and Ophthalmology annual meeting May 3-7, 2009 in Ft.

Mike Baird/Caller-Times Retired air conditioner repairman John Harris hands a pepper container filled with mercury to landfill manager Tony Benavides.

May 4, 2009 - Inspire Pharmaceuticals, Inc. announced today the presentation of data related to post-marketing open-label clinical and nonclinical work with AzaSite 1% in poster presentations at the 2009 Association for Research in Vision and Ophthalmology annual meeting May 3-7, 2009 in Ft.

May 4, 2009 - Inspire Pharmaceuticals, Inc. announced today it has initiated a Phase 2 program with AzaSite 1% to pursue a potential indication for the treatment of blepharitis, an ocular disease characterized by inflammation of the eyelids.

Apr 28, 2009 - Cempra Pharmaceuticals today announced the publication of new research in the May issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology, demonstrating that its lead compound, CEM-101, is active in vitro against six clinically important human Mycoplasma and Ureaplasma species.

The growing ineffectiveness of a popular and widely requested antibiotic has local doctors emphasizing the importance of responsible antibiotic use.

Under the terms of the agreement, Nitten is responsible for obtaining regulatory approval and has exclusive rights to commercialise AzaSite for ocular bacterial infection in Japan and Taiwan.

DHAKA: The directorate of drug administration has notified Advanced Chemical Industries Limited to explain its illegal import of an antibiotic raw material from an unauthorised source submitting fake document.

InSite Vision Incorporated today announced that the Therapeutic Products Directorate of Health Canada has approved the company's new drug submission for AzaSite 1% for the treatment of bacterial conjunctivitis in adults and children one year and older.

Sagent will offer azithromycin in a 500 mg vial for intravenous use. The Company anticipates the launch of azithromycin in April 2009.

Company Expects 367% Increase in Monthly Revenue Generated by the Drug Increased Market Share to Drive Approximately $3.7 million in Revenue Growth During Next 12 Months a a CHENGDU, China, March 17 ...